Fair value · LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) · updated 2026-10-23 · from 10-K FY2026
LIFECORE BIOMEDICAL, INC. \DE\ trades at $6.37. That price implies 37.5× EV/EBITDA and a 2.6% free-cash-flow yield.
Cboe · delayed 15 min · as of 20:04 ET
Are those assumptions reasonable? Use LFCR’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- EV/EBITDA
- 37.5×
- FCF yield
- 2.6%
(market cap + net debt) ÷ EBITDA
free cash flow ÷ enterprise value (38.4× EV/FCF)
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 20:04 ET.
With preset inputs the methods land at $1.68 – $2.51 (presets are filed history and our reference settings, not a recommendation)
How each method got its number
Bear, base and bull are the 25th, 50th and 75th percentile of the methods that produced a usable estimate. Weights say how much a method is trusted for this sector; they do not change the range.
| Method | Estimate | vs price | Weight | Why this method |
|---|---|---|---|---|
DCF High weight Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions. | $1.66 | -74% | High weight | Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions. |
EV/EBITDA Medium weight Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it. | $1.70 | -73% | Medium weight | Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it. |
EV/FCF Medium weight 20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing. Based on latest annual FCF (quarterly TTM unavailable) | $3.32 | -48% | Medium weight | 20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing. |
P/E vs sector Medium weight Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer. Negative or unavailable EPS | No estimate | Medium weight | Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer. | |
Growth-trajectory DCF Medium weight A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate. No trajectory data available | No estimate | Medium weight | A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate. | |
P/B vs sector Medium weight Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software. P/B comparable is optional for non-financial companies | No estimate | Medium weight | Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software. | |
Graham Number Medium weight Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech. Requires positive EPS | No estimate | Medium weight | Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech. | |
Earnings Power Value Medium weight Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth. estimate at or below $0, or more than 4× away from the price | Not meaningful for this company | Medium weight | Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth. | |
What this means
- The methods differ by about 49%, from $1.68 to $2.51. That is normal: cash-flow methods and peer multiples see different things. Use the range, not a single number.
- The base case, $1.70, is the median of the 3 methods with data. It assumes LIFECORE BIOMEDICAL, INC. \DE\’s current margins, cash generation and share count persist; it does not price in a new product cycle, a recession or a buyback surge.
- The number moves when the filings move. The next 10-Q replaces the oldest quarter in the trailing-twelve-month EPS and cash-flow inputs; the last one (Q4 FY2026) was filed 2026-03-16. The price changes every day; the fair value only changes with the filings.
The filing behind these numbers
LIFECORE BIOMEDICAL, INC. \DE\- Revenue
- $34.2M
- Diluted EPS
- $-0.19
- Free cash flow
- —
- operating cash flow − capital expenditure
- Diluted shares
- 37.6M
- weighted average
10-K FY2026 · fiscal year ended 2026-12-31 · filed 2026-03-16
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q4 FY2026 (filed 2026-03-16).
Open the 10-K list on sec.govCIK 1005286